SAN CARLOS, Calif., Oct. 13, 2015 /PRNewswire/ -- Rosa & Co. LLC, the leading commercial drug development advisory firm in Quantitative Systems Pharmacology (QSP)/PhysioPD™, today announced that Dr. Christina Friedrich, Chief Engineer, will lead a workshop at the QSP Congress Meeting on October 20th, 2015 in Boston, MA. The conference focuses on the uses and benefits of QSP in pharmaceutical drug development. Dr. Friedrich's workshop is entitled "Using Mechanistic Physiological Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) Approach", and will discuss the use of a systematic approach for model development and qualification, Rosa's Model Qualification Method (MQM). Case studies and model examples will illustrate application of the MQM process to ensure that QSP models are fit for purpose and support actionable insights.
In recent years, QSP has emerged as a powerful research approach that enables scientific insight and informs early discovery to clinical development decisions. The most innovative R&D organizations in the industry are increasingly adopting QSP as an essential component of model-informed decision-making. Rosa's participation in a 4th major QSP conference in 2015 further demonstrates its role in expanding the adoption of QSP as a standard research method within the pharmaceutical industry.
"Rosa & Co. is honored to share our perspective, gained from over 12 years of experience growing our practice, on modeling processes and the impact of PhysioPD-based biological research to support decision-making in the pharmaceutical industry."
- Dr. Ananth Kadambi, Senior Vice President, PhysioPD™, Rosa & Co. LLC
Rosa supports clients with their critical decisions – from preclinical through clinical development – by creating and using customized PhysioPD™ Research Platforms that simulate normal and disease physiology, drug action, patient variability, and trial outcomes, thereby reducing R&D challenges translating targets to outcomes. Rosa's clients participate in Platform creation, testing, and biological simulation research. Clients retain the Platform as a program asset to support decisions and perform future research. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to impact drug development and has over 13 years of client engagements in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area experience, including metabolic diseases, immuno-oncology, oncology, cardiovascular, inflammation, immune dysfunction, central nervous system disorders, dermatology, and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com/news.html.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
SOURCE Rosa & Co. LLC